![[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!](https://businessfortnight.com/wp-content/uploads/2025/10/Toyota-Times-Century-as-a-Brand-Lexus-as-Innovation-All-218x150.jpg "[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!")
ORION CORPORATION
STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE
19 SEPTEMBER 2022 at 9.30 EEST
165,797 Orion Corporation A shares converted into B shares
In accordance with Section 3 of the Articles of Association of Orion Corporation, 165,797 A shares have been converted into 165,797 B shares. The conversion has been entered into the Trade Register on 19 September 2022.
The whole variety of shares in Orion Corporation is 141,134,278 which, after the conversion, consists of 34,310,524 A shares and 106,823,754 B shares. The variety of votes of the corporate’s shares is after the conversion 793,034,234.
Orion Corporation
| Jari Karlson
CFO |
Olli Huotari
SVP, Corporate Functions |
Contact individual:
Tuukka Hirvonen, Investor Relations, tel. +358 10 426 2721
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
www.orion.fi
Orion is a globally working Finnish pharmaceutical firm – a builder of well-being. Orion develops, manufactures and markets human and veterinary prescription drugs and lively pharmaceutical elements. The firm is constantly creating new medication and therapy strategies. The core remedy areas of Orion’s pharmaceutical R&D are oncology and ache. Orion’s web gross sales in 2021 amounted to EUR 1,041 million and the corporate had about 3,350 workers on the finish of the 12 months. Orion’s A and B shares are listed on Nasdaq Helsinki.
